Serum PDGF-AB in pleural mesothelioma

Rosa Filiberti, Paola Marroni, Monica Neri, Andrea Ardizzoni, Pier Giacomo Betta, Mara A. Cafferata, Pier Aldo Canessa, Riccardo Puntoni, Giovanni Paolo Ivaldi, Michela Paganuzzi

Research output: Contribution to journalArticle

Abstract

Overexpression of platelet-derived growth factor (PDGF) has been observed in lung and pleural tumors. The aim of this study was to evaluate the diagnostic and prognostic role of serum PDGF in pleural mesothelioma (PM). Four groups of subjects were studied: 93 malignant PM patients, 33 primary non small cell lung cancer patients, 51 subjects exposed to asbestos, defined as high-risk controls, and 24 healthy controls. PDGF-AB mean concentration was higher in PM patients (45.8 ng/ml) than in high-risk controls (33.1 ng/ml) and healthy controls (26.8 ng/ml). Using the cut-off level of 49.8 ng/ml, corresponding to the mean + 2SD of PDGF-AB in healthy controls, 43% of PM patients showed positive PDGF-AB levels. Survival was evaluated in 82 PM patients. At the end of the follow-up (median 9.8 months) 80.5% of patients had died. Median survival was 13.1 and 7.9 months for patients with PDGF-AB lower and higher than the cut-off, respectively. Adjusting for age, sex, histology and platelet count, positive PDGF-AB levels were associated with lower survival (OR = 1.2, 95%CI: 0.9-1.6), even if not significantly so. In conclusion, serum PDGF may represent a useful additional parameter to prognostic factors already available for PM.

Original languageEnglish
Pages (from-to)221-226
Number of pages6
JournalTumor Biology
Volume26
Issue number5
DOIs
Publication statusPublished - Sep 2005

Fingerprint

Mesothelioma
Serum
Platelet-Derived Growth Factor
Survival
Asbestos
platelet-derived growth factor AB
Platelet Count
Non-Small Cell Lung Carcinoma
Histology
Lung
Neoplasms

Keywords

  • Asbestos
  • Biomarker
  • Growth factor
  • PDGF
  • Pleural mesothelioma
  • Prognosis
  • Serum

ASJC Scopus subject areas

  • Cancer Research

Cite this

Filiberti, R., Marroni, P., Neri, M., Ardizzoni, A., Betta, P. G., Cafferata, M. A., ... Paganuzzi, M. (2005). Serum PDGF-AB in pleural mesothelioma. Tumor Biology, 26(5), 221-226. https://doi.org/10.1159/000087376

Serum PDGF-AB in pleural mesothelioma. / Filiberti, Rosa; Marroni, Paola; Neri, Monica; Ardizzoni, Andrea; Betta, Pier Giacomo; Cafferata, Mara A.; Canessa, Pier Aldo; Puntoni, Riccardo; Ivaldi, Giovanni Paolo; Paganuzzi, Michela.

In: Tumor Biology, Vol. 26, No. 5, 09.2005, p. 221-226.

Research output: Contribution to journalArticle

Filiberti, R, Marroni, P, Neri, M, Ardizzoni, A, Betta, PG, Cafferata, MA, Canessa, PA, Puntoni, R, Ivaldi, GP & Paganuzzi, M 2005, 'Serum PDGF-AB in pleural mesothelioma', Tumor Biology, vol. 26, no. 5, pp. 221-226. https://doi.org/10.1159/000087376
Filiberti R, Marroni P, Neri M, Ardizzoni A, Betta PG, Cafferata MA et al. Serum PDGF-AB in pleural mesothelioma. Tumor Biology. 2005 Sep;26(5):221-226. https://doi.org/10.1159/000087376
Filiberti, Rosa ; Marroni, Paola ; Neri, Monica ; Ardizzoni, Andrea ; Betta, Pier Giacomo ; Cafferata, Mara A. ; Canessa, Pier Aldo ; Puntoni, Riccardo ; Ivaldi, Giovanni Paolo ; Paganuzzi, Michela. / Serum PDGF-AB in pleural mesothelioma. In: Tumor Biology. 2005 ; Vol. 26, No. 5. pp. 221-226.
@article{dc644a9726f64488900384c7072eabd3,
title = "Serum PDGF-AB in pleural mesothelioma",
abstract = "Overexpression of platelet-derived growth factor (PDGF) has been observed in lung and pleural tumors. The aim of this study was to evaluate the diagnostic and prognostic role of serum PDGF in pleural mesothelioma (PM). Four groups of subjects were studied: 93 malignant PM patients, 33 primary non small cell lung cancer patients, 51 subjects exposed to asbestos, defined as high-risk controls, and 24 healthy controls. PDGF-AB mean concentration was higher in PM patients (45.8 ng/ml) than in high-risk controls (33.1 ng/ml) and healthy controls (26.8 ng/ml). Using the cut-off level of 49.8 ng/ml, corresponding to the mean + 2SD of PDGF-AB in healthy controls, 43{\%} of PM patients showed positive PDGF-AB levels. Survival was evaluated in 82 PM patients. At the end of the follow-up (median 9.8 months) 80.5{\%} of patients had died. Median survival was 13.1 and 7.9 months for patients with PDGF-AB lower and higher than the cut-off, respectively. Adjusting for age, sex, histology and platelet count, positive PDGF-AB levels were associated with lower survival (OR = 1.2, 95{\%}CI: 0.9-1.6), even if not significantly so. In conclusion, serum PDGF may represent a useful additional parameter to prognostic factors already available for PM.",
keywords = "Asbestos, Biomarker, Growth factor, PDGF, Pleural mesothelioma, Prognosis, Serum",
author = "Rosa Filiberti and Paola Marroni and Monica Neri and Andrea Ardizzoni and Betta, {Pier Giacomo} and Cafferata, {Mara A.} and Canessa, {Pier Aldo} and Riccardo Puntoni and Ivaldi, {Giovanni Paolo} and Michela Paganuzzi",
year = "2005",
month = "9",
doi = "10.1159/000087376",
language = "English",
volume = "26",
pages = "221--226",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "5",

}

TY - JOUR

T1 - Serum PDGF-AB in pleural mesothelioma

AU - Filiberti, Rosa

AU - Marroni, Paola

AU - Neri, Monica

AU - Ardizzoni, Andrea

AU - Betta, Pier Giacomo

AU - Cafferata, Mara A.

AU - Canessa, Pier Aldo

AU - Puntoni, Riccardo

AU - Ivaldi, Giovanni Paolo

AU - Paganuzzi, Michela

PY - 2005/9

Y1 - 2005/9

N2 - Overexpression of platelet-derived growth factor (PDGF) has been observed in lung and pleural tumors. The aim of this study was to evaluate the diagnostic and prognostic role of serum PDGF in pleural mesothelioma (PM). Four groups of subjects were studied: 93 malignant PM patients, 33 primary non small cell lung cancer patients, 51 subjects exposed to asbestos, defined as high-risk controls, and 24 healthy controls. PDGF-AB mean concentration was higher in PM patients (45.8 ng/ml) than in high-risk controls (33.1 ng/ml) and healthy controls (26.8 ng/ml). Using the cut-off level of 49.8 ng/ml, corresponding to the mean + 2SD of PDGF-AB in healthy controls, 43% of PM patients showed positive PDGF-AB levels. Survival was evaluated in 82 PM patients. At the end of the follow-up (median 9.8 months) 80.5% of patients had died. Median survival was 13.1 and 7.9 months for patients with PDGF-AB lower and higher than the cut-off, respectively. Adjusting for age, sex, histology and platelet count, positive PDGF-AB levels were associated with lower survival (OR = 1.2, 95%CI: 0.9-1.6), even if not significantly so. In conclusion, serum PDGF may represent a useful additional parameter to prognostic factors already available for PM.

AB - Overexpression of platelet-derived growth factor (PDGF) has been observed in lung and pleural tumors. The aim of this study was to evaluate the diagnostic and prognostic role of serum PDGF in pleural mesothelioma (PM). Four groups of subjects were studied: 93 malignant PM patients, 33 primary non small cell lung cancer patients, 51 subjects exposed to asbestos, defined as high-risk controls, and 24 healthy controls. PDGF-AB mean concentration was higher in PM patients (45.8 ng/ml) than in high-risk controls (33.1 ng/ml) and healthy controls (26.8 ng/ml). Using the cut-off level of 49.8 ng/ml, corresponding to the mean + 2SD of PDGF-AB in healthy controls, 43% of PM patients showed positive PDGF-AB levels. Survival was evaluated in 82 PM patients. At the end of the follow-up (median 9.8 months) 80.5% of patients had died. Median survival was 13.1 and 7.9 months for patients with PDGF-AB lower and higher than the cut-off, respectively. Adjusting for age, sex, histology and platelet count, positive PDGF-AB levels were associated with lower survival (OR = 1.2, 95%CI: 0.9-1.6), even if not significantly so. In conclusion, serum PDGF may represent a useful additional parameter to prognostic factors already available for PM.

KW - Asbestos

KW - Biomarker

KW - Growth factor

KW - PDGF

KW - Pleural mesothelioma

KW - Prognosis

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=24144456982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24144456982&partnerID=8YFLogxK

U2 - 10.1159/000087376

DO - 10.1159/000087376

M3 - Article

C2 - 16103743

AN - SCOPUS:24144456982

VL - 26

SP - 221

EP - 226

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 5

ER -